CatalYm GmbH remote jobs and company guide

CatalYm is developing an immunotherapy approach built around targeting GDF-15, which the company describes as a key cancer therapy resistance mechanism. CatalYm’s lead program centers on visugromab (CTL-002), a monoclonal antibody engineered to neutralize tumor-derived GDF-15, an immunosuppressive factor that the company states helps cancer cells evade immune attacks. According to CatalYm, neutralizing GDF-15 can reverse important resistance mechanisms by reenabling immune cell activation and tumor infiltration, and the program has been evaluated in combination strategies including anti-PD-1.

The company frames its work as advancing visugromab through clinical development to confirm its potential as a new class of cancer immunotherapy across multiple solid tumor indications, including in combination with checkpoint inhibitors and across different treatment lines. On its website, CatalYm also describes visugromab as having potential to address treatment-related side effects associated with GDF-15 expression, including cachexia-related symptoms. CatalYm is headquartered in Germany, and its corporate leadership includes a CEO overseeing both EU and US operations.